Neurogene Stock (NASDAQ: NGNE) stock price, news, charts, stock research, profile.
Open | $33.590 |
Close | - |
Volume / Avg. | 29.672K / 136.278K |
Day Range | 33.000 - 35.210 |
52 Wk Range | 12.490 - 53.000 |
Market Cap | $409.528M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 8.76% |
Days to Cover | 11.33 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Neurogene (NASDAQ: NGNE) through any online brokerage.
Other companies in Neurogene’s space includes: Voyager Therapeutics (NASDAQ:VYGR), PepGen (NASDAQ:PEPG), Replimune Group (NASDAQ:REPL), Fate Therapeutics (NASDAQ:FATE) and Anika Therapeutics (NASDAQ:ANIK).
The latest price target for Neurogene (NASDAQ: NGNE) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst firm set a price target for 51.00 expecting NGNE to rise to within 12 months (a possible 48.43% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Neurogene (NASDAQ: NGNE) is $34.36 last updated Today at May 16, 2024 at 1:41 PM EDT.
There are no upcoming dividends for Neurogene.
Neurogene’s Q2 earnings are confirmed for Thursday, August 15, 2024.
There is no upcoming split for Neurogene.
Neurogene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.